Dark Streaming/Mobile Old Site Home Daily Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:07:01 EDT Tue 28 Mar 2023
Enter Symbol
or Name
USA
CA



News for U:RNAZ from 2022-03-29 to 2023-03-28 - 27 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2023-02-28 07:00U:RNAZNews ReleaseTransCode Therapeutics Announces Orphan Drug Designation Status for TTX-MC138 for Treatment of Pancreatic Cancer
2023-02-22 08:00U:RNAZNews ReleaseTransCode Therapeutics and BRAIN Biotech join forces to develop a CRISPR-derived technology platform for cancer treatment
2023-02-17 16:10U:RNAZNews ReleaseTransCode Therapeutics Announces Closing of $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
2023-02-16 08:00U:RNAZNews ReleaseTransCode Therapeutics Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
2023-01-31 16:05U:RNAZNews ReleaseTransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma
2022-12-29 08:00U:RNAZNews ReleaseTransCode Therapeutics Announces FDA Authorization to Proceed with First-In-Human Clinical Trial
2022-12-06 16:20U:RNAZNews ReleaseTransCode Therapeutics Announces Withdrawal of Registration Statement
2022-11-30 07:00U:RNAZNews ReleaseTransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors
2022-11-14 16:15U:RNAZNews ReleaseTransCode Therapeutics Reports Third Quarter 2022 Results; Provides Business Update
2022-11-09 07:00U:RNAZNews ReleaseTransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma
2022-11-08 15:44U:RNAZNews ReleaseSidoti's November Micro-Cap Virtual Conference
2022-11-07 08:00U:RNAZNews ReleaseTransCode Therapeutics to Present at Sidoti Virtual Investor Conference
2022-10-26 07:00U:RNAZNews ReleaseTransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma
2022-10-19 08:02U:RNAZNews ReleaseTransCode Therapeutics: Invitation to The ThinkEquity Conference
2022-10-13 07:00U:RNAZNews ReleaseTransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology
2022-09-27 08:00U:RNAZNews ReleaseTransCode Therapeutics to Participate at the Chardan 6th Annual Genetic Medicines Conference
2022-09-08 08:00U:RNAZNews ReleaseTransCode Therapeutics Appoints MicroRNA Pioneer, Dr. Frank Slack, to its Advisory Board
2022-08-15 16:15U:RNAZNews ReleaseTransCode Therapeutics Reports Second Quarter 2022 Results; Provides Business Update
2022-08-02 07:00U:RNAZNews ReleaseTransCode Therapeutics and MD Anderson Announce Strategic Alliance to Advance RNA Therapies for Oncology
2022-07-11 16:05U:RNAZNews ReleaseTransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio
2022-06-09 09:00U:RNAZNews ReleaseTransCode Therapeutics to Participate at BIO International Convention
2022-06-01 09:00U:RNAZNews ReleaseTransCode Therapeutics Receives National Institutes of Health (NIH) Notice of Award
2022-05-20 09:00U:RNAZNews ReleaseTransCode Therapeutics To Participate at H.C. Wainwright Global Investment Conference
2022-05-19 09:00U:RNAZNews ReleaseTransCode Therapeutics Acquires Option for Radiotheranostic Technology
2022-05-16 08:30U:RNAZNews ReleaseTransCode Therapeutics Reports First Quarter 2022 Results; Provides Business Update
2022-04-13 09:00U:RNAZNews ReleaseTransCode Therapeutics' CTO, Dr. Zdravka Medarova, to Moderate 7th Annual RNA Medicine Symposium
2022-03-31 16:30U:RNAZNews ReleaseTransCode Therapeutics Reports 2021 Results; Provides Business Update